RESEARCH CATALOG

GLP-3 Shredatrutide — Retatrutide

Retatrutide (LY3437943) is listed in the Peptide Tactics catalog under the designation GLP-3 Shredatrutide, and is available to order as research material in India as a 10 mg lyophilized vial. GLP-3 Shredatrutide is the catalog designation this business uses for the product; retatrutide, or LY3437943, is the scientific and reference name used in the published literature. Catalog information appears below under the first name and scientific reference data under the second, so that the two are never confused for one another.

Retatrutide, also identified by the development code LY3437943, is an investigational peptide currently in clinical development, and is described in published research as a triple agonist of the GLP-1, GIP and glucagon receptors. Published chemical records exist for it, but the molecular mass that applies depends on which chemical form is being described, and the reference data below sets out which record each value comes from.

Peptide Tactics GLP-3 Shredatrutide (retatrutide) 10 mg research material vial

Catalog price₹3,49910 mg • lyophilized powder

Enquiries are completed over WhatsApp or email. Peptide Tactics provides information and distribution for qualified research use. See the research-use policy before ordering.

Also written as

LY3437943 · GLP-3 Shredatrutide · Shredatrutide

Compound identity

Development code	LY3437943(PMID 35985340)
CAS registry number	2381089-83-2 is widely cited for retatrutide, but is not listed in the PubChem records below and is not verified here(unverified — see notes)
Receptor classification	Triple agonist of the GLP-1, GIP and glucagon receptors, as characterised in published pharmacology(PMID 35985340)
Record naming	CID 171390338 is titled “Triple G” and carries the parent formula; the record explicitly titled retatrutide is the sodium salt, CID 171934787(PubChem)
Molecular formula (parent peptide)	C221H342N46O68(PubChem CID 171390338)
Molecular weight (parent peptide)	4731 g/mol; monoisotopic 4728.47 Da(PubChem CID 171390338)
Separate salt record	Retatrutide sodium is indexed separately, with the same computed parent formula and mass(PubChem CID 171934787)
Development status	Investigational; studies listed through Phase 3, including NCT06354660(ClinicalTrials.gov)
Form of supplied material	Not established — see the notes below this table(catalog information)
Catalog format	10 mg • lyophilized powder(catalog information)

Each row above is attributed to its source. Rows citing a database record are reference information about the molecule; rows marked catalog information describe this listing. Neither is a specification, an analytical result or a claim about any particular batch.

Research classification

Investigational peptide in clinical development. Not approved by any regulator for any indication. Characterised in the published pharmacology literature as a single molecule with agonist activity at three receptors: GLP-1, GIP and glucagon (Coskun et al., Cell Metabolism, 2022; PMID 35985340). That is a description of how the molecule is classified in published research. It is not a statement about efficacy, safety, human use or suitability for any purpose.

Chemical characteristics

Retatrutide is described in published pharmacology as a triple agonist at the GLP-1, GIP and glucagon receptors. That classification describes the molecule as studied in research; it says nothing about the material in any particular vial, and nothing on this page should be read as a claim about what that material does.
Retatrutide is a considerably larger and more structurally elaborate molecule than the short research peptides elsewhere in this catalog, and characterising it is correspondingly more demanding.
Molecules of this class are typically lipidated to extend circulating half-life, which affects chromatographic retention and complicates the interpretation of a simple purity percentage.
At around 4731 g/mol the parent peptide sits well above the mass range of the other peptides listed here, and electrospray analysis will produce a broad multiply charged envelope requiring deconvolution rather than a single readable mass.

Analytical methods

Reversed-phase HPLC (RP-HPLC) is the method most commonly used to express the chromatographic purity of a synthetic peptide as a percentage of total peak area at a stated wavelength.
Mass spectrometry (typically ESI-MS or MALDI-TOF) is used to confirm that the observed mass of the material is consistent with the expected mass of the intended sequence.
Because purity figures are method-dependent, an analytical result is only interpretable alongside the method conditions and the batch it describes.

Both methods are covered in more detail in our guides to HPLC analysis of peptides and mass spectrometry for identity confirmation.

Stability and storage considerations

Lyophilized peptides are generally supplied as a dry solid because the removal of water slows hydrolytic degradation pathways.
Cold, dry, light-protected storage is the general handling expectation for lyophilized research peptides.
Once a peptide is taken into solution, its stability profile changes and is influenced by solvent, pH, temperature and the number of freeze-thaw cycles.
Storage and handling expectations for a specific batch should be taken from that batch's documentation rather than from general guidance.

See peptide stability and degradation for the chemistry behind these considerations.

What this page does not claim

Retatrutide is not an approved medicine anywhere. It is an investigational compound, and no approved indication, dosage form or route of administration exists for it.
Peptide Tactics makes no statement about efficacy, safety, metabolic effects or body composition. The receptor classification given above is a published pharmacological description of the molecule, not an outcome claim. Published clinical trial information relates to the investigational compound under study conditions and does not describe any material supplied through this catalog.
The formula and mass above describe the parent peptide as computed by PubChem. They are not a specification for supplied material. Retatrutide is indexed in public databases under more than one chemical form, including a sodium-salt record, and any real preparation will also carry counter-ions and residual water that the parent record does not account for.
Two identifier caveats apply to this page. The CAS number 2381089-83-2 is commonly cited for retatrutide across chemical suppliers, but it does not appear in the synonym list of either PubChem record used here, so it is reported as unverified rather than asserted. Separately, the parent-peptide record CID 171390338 is titled “Triple G” rather than retatrutide; the record carrying the retatrutide name is the sodium salt, CID 171934787. The two share the same computed parent formula.
Peptide Tactics has not established which chemical form or salt the material supplied under this listing corresponds to, and this page should not be read as asserting a particular form. That must be confirmed from applicable batch documentation where available, or by independent analysis.

Independent Analytical Documentation

Janoshik Analytical verification

Catalog products are independently verified through Janoshik Analytical. Certificates of analysis from that laboratory are issued per product and per batch — not as a single generic document for the whole catalog — so the report you receive describes the material you are ordering.

Should you require a Janoshik COA for GLP-3 Shredatrutide, write to us on WhatsApp and we will provide the applicable report for that product.

Request Janoshik COA on WhatsApp

We do not currently publish a full independent analytical report on this page for the GLP-3 Shredatrutide listed here. That does not mean documentation is unavailable — it means the report is supplied on request for the batch being fulfilled, rather than attached permanently to a catalog listing that outlives any one batch.

If a report is a requirement for your work, ask before ordering. We will check what Janoshik or other documentation covers the current batch and tell you what it is. Where nothing exists for that batch, we will say so.

Reading the documentation matters as much as having it. Our guides on how to read a peptide certificate of analysis and what a purity figure does and does not mean cover what to look for, and our documentation page explains the request process.

Ordering GLP-3 Shredatrutide in India

GLP-3 Shredatrutide is ordered through the catalog and finalised over WhatsApp or email, so that any question about specification or documentation is settled before the order is placed rather than after it.

Immediate dispatch whenever couriers are operating. Orders from Bangalore are dispatched immediately whenever courier operations are open. Orders from elsewhere in India are dispatched as soon as couriers are operating.

Distribution is within India. Material is supplied for in-vitro research and analytical applications only, and we do not supply for human or veterinary use.

Order for Research Use Enquire About GLP-3 Shredatrutide

Frequently asked questions

What is GLP-3 Shredatrutide?: GLP-3 Shredatrutide is the catalog designation Peptide Tactics uses for retatrutide (LY3437943). It is a product name, not a scientific one. There is no receptor or peptide class called GLP-3, and this site does not use the term as a chemical or pharmacological classification anywhere.
Is GLP-3 Shredatrutide the same as retatrutide?: They refer to the same material, but they are different kinds of name. The Peptide Tactics catalog lists the product under the designation GLP-3 Shredatrutide. Retatrutide, and its development code LY3437943, are the names used for the compound in published scientific literature and in chemical databases. Shredatrutide is not a recognised scientific synonym and we do not present it as one.
What is retatrutide?: Retatrutide is an investigational peptide in clinical development, characterised in the published pharmacology literature as a triple agonist of the GLP-1, GIP and glucagon receptors (Coskun et al., Cell Metabolism, 2022; PMID 35985340). That is how the molecule is classified in research. It is not an approved medicine anywhere, and the classification is not a statement about efficacy, safety, human use or what any supplied material does.
What is LY3437943?: LY3437943 is the development code for retatrutide, used in the clinical and pharmacology literature including the receptor characterisation published by Coskun et al. in Cell Metabolism, 2022 (PMID 35985340). Searches for LY3437943 and for retatrutide refer to the same compound.
Can I buy retatrutide in India?: Peptide Tactics lists the relevant research material in its India catalog under the designation GLP-3 Shredatrutide, as a 10 mg lyophilized vial with the price shown on this page. It can be ordered for research use, with orders finalised over WhatsApp or email. It is supplied for in-vitro research and analytical applications only, and not for human or veterinary use. Before ordering, read the identity section on this page: the chemical form of the supplied material is not something we have established.
What is the molecular weight of retatrutide?: PubChem records the parent peptide with a molecular formula of C221H342N46O68, a molecular weight of 4731 g/mol and a monoisotopic mass of 4728.47 Da (CID 171390338). That is reference data describing the parent molecule, not a measurement of any supplied batch. A real preparation supplied as a salt weighs more per vial, because counter-ions and residual water contribute mass the parent record excludes.
What is the chemical formula and sequence of retatrutide?: The parent peptide formula on record is C221H342N46O68 (PubChem CID 171390338). Retatrutide is a large lipidated peptide rather than a short unmodified sequence, and PubChem does not publish it as a simple one-letter amino acid string in the way it does for the shorter peptides in this catalog, so no sequence is reproduced here. Inventing one would be worse than omitting it.
What receptors does retatrutide act on?: Published pharmacology characterises retatrutide (LY3437943) as a triple agonist of the GLP-1, GIP and glucagon receptors (PMID 35985340). Note that GLP-3, which appears in the catalog designation, is not one of them — no such receptor exists. Peptide Tactics makes no claim about efficacy, safety or suitability for any use.
Is retatrutide an approved medicine?: No. Retatrutide is an investigational compound. ClinicalTrials.gov records show studies through Phase 3, including NCT06354660, but it has not been approved by a regulator for any indication, and it is listed in this catalog strictly as a research material.
Which chemical form does the Peptide Tactics listing correspond to?: We have not established that. Retatrutide is indexed under more than one form, including a sodium-salt record, and this page deliberately does not claim which one applies to supplied material. Confirming it requires the applicable batch documentation or independent analysis.
Is there an analytical report or COA for retatrutide?: We do not hold a published independent analytical report for the material currently listed, and we do not claim one. Analytical documentation is available on request where it exists for the batch being supplied — that may be a supplier certificate of analysis, an independent laboratory report, or nothing. Ask before ordering and we will tell you which it is. Our guides to reading a certificate of analysis and to what HPLC purity figures mean explain how to assess whatever arrives.
How quickly are orders dispatched?: Dispatch is immediate whenever courier services are operating. Bangalore orders take priority in the dispatch queue; orders from elsewhere in India go out as soon as couriers are running, and anything received outside courier hours is dispatched when they reopen. We do not quote a delivery date, because transit time is the courier's and not ours.
Can you source a compound that is not listed?: Yes. Our catalog is what we currently hold, not the limit of what we can look into. Send the compound name, quantity and any specification that matters — salt form, purity threshold, documentation requirement — and we will investigate sourcing options and tell you what is possible, what it would cost and what documentation exists.
Is this material intended for human use?: No. Everything in this catalog is supplied for in-vitro research and analytical applications only, and not for human or veterinary use. We do not provide dosing, administration guidance or any therapeutic recommendation, and we cannot supply material for those purposes.

Sources

Can't Find the Compound You Need?

Our catalog lists what we currently hold, and it is not the full range of research materials we can look into. If you need a compound that is not listed, tell us what you are looking for and we will investigate sourcing options for it.

Useful things to include in your enquiry:

The compound name, and any code or CAS number you have for it.
Quantity per vial, and how many vials.
Any specification that matters to your work — salt form, purity threshold, or the analytical method you need it reported against.
Whether batch documentation or an independent analytical report is a requirement, so we can establish up front whether it is available.

We will tell you what we can source, what it would cost and what documentation exists. Where we cannot source something, or cannot establish its documentation, we will say so rather than take the order.

Request a Compound Enquire by Email

Sourcing enquiries are accepted for in-vitro research and analytical use only. We cannot supply material for human or veterinary use, and we do not advise on how any compound should be used.

BPC-157

Buy BPC-157 in India from Peptide Tactics. 10 mg research vial, listed pricing, verified sequence and molecular data, documentation on request.

View compound page

MOTS-c

Buy MOTS-C in India from Peptide Tactics. 10 mg research vial with listed pricing, 16-residue sequence, molecular data and oxidation notes. Research use only.